Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells

Journal of Cellular Physiology

Volumn 214, Issue 3, 2008, Pages 714-720

  George, Kerri L ^a   Saltman, Laura H ^a   Stein, Gary S ^a   Lian, Jane B ^a   Zurier, Robert B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AJULEMIC ACID; CANNABINOID DERIVATIVE; CASPASE; LIPOCORTIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; PROPIDIUM IODIDE; CANNABINOID; DRUG DERIVATIVE; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE EROSION; BONE MARROW CULTURE; CELL ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; GROWTH INHIBITION; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEM CELL; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; MACROPHAGE;

CANNABIS; DIOSCOREA TRIFIDA; RATTUS;

ANIMALS; APOPTOSIS; CANNABINOIDS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; MICE, INBRED BALB C; OSTEOCLASTS; PSYCHOTROPIC DRUGS; RANK LIGAND; STEM CELLS; TETRAHYDROCANNABINOL;

EID: 38449111261     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21263     Document Type: Article

References (30)

1. Ambrosio ALB, Dias SMG, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. 2007. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem 282:18625-18633.
2. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
3. Burstein SH. 1999. The cannabinoid acids: Nonpsychoactive derivatives with therapeutic potential. Pharmacol Therap 82:87-96.
4. 1- tetrahydrocannabinol. Science 176:422-424.
5. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R. 1992. Synthetic non-psychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte anti-adhesion activities. J Med Chem 35:3135-3141.
6. Dajani EZ, Larsen KR, Taylor J, Dajani NE, Shawan TG, Neelema SD, Taylor MS, Dayton MT, Mir GN. 1999. 1′1′ dimethylheptyl-Δ8 tetrahydrocannabinol-11 oic acid: A novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J Pharmacol Exp Ther 291:31-38.
7. Dimarzo V, DePetrocellis L, Fezza F, Ligresti A, Bisogno T. 2002. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66:377-391.
8. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. 2004. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: Novel role for endogenous an exogenous cannabinoids in immunoregulation. J Immunol 173:2373-2382.
9. Gravallese EM. 2002. Bone destruction in arthritis. Ann Rheum Dis 61:84-86.
10. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of R AW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366-47372.
11. Hsu H, Lacey D, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia X, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass M, Boyle W. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci 96:3540-3545.
12. Idris A, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH. 2005. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774-779.
13. Liu J, Li H, Burstein SH, Zurier RB, Chen JD. 2003. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63:983-992.
14. Karsak M, Ofek O, Fogel M, Wright K, Tam J, Gabet Y, Birenboim R, Attar-Namdar M, Müeller R, Cohen-Solal M. 2004. The cannabinoid CB2 receptor: A potential target for the treatment of osteoporosis. J Bone Miner Res 19:S383.
15. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. 2003. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 290:1757-1762.
16. Kotakeetal S, Sato K., et al. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast like cell formation. J Bone Miner Res 11:88-95.
17. Lacey DL, Timma E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
18. Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. 2007. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 100:184-190.
19. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. 2006. Peripheral cannabinoid receptor, CB2, regulates bone mass. Prot Natl Acad Sci 103:696-701.
20. Raisz LG. 2005. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115:3318-3325.
21. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R. 1997. Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40:3228-3233.
22. Rodan GA, Martin TJ. 2000. Therapeutic approaches to bone diseases. Science 289:1508-1514.
23. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
24. Teitelbaum SL. 2007. Osteoclasts: What do they do and how do they do it? Am J Pathol 170:427-435.
25. Wei S., et al. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282-290.
26. Wyllie AH, Morris RG, Smith AL, Dunlop D. 1984. Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142:67-77.
27. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
28. Zurier RB. 2003. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 88:462-466.
29. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. 1998. Dimethylheptyl-THC-11 oic acid: A nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis Rheum 41:163-170.
30. Zurier RB, Rosetti RG, Burstein SH, Bidinger B. 2003a. Suppression of human monocytes interleukin 1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65:649-655.